NEW YORK (GenomeWeb) – Researchers from Oregon Health & Science University, MD Anderson Cancer Center, and NanoString Technologies have validated the company's nCounter platform for quantifying proteins in tumor cell lysates.
The work, published last week in Molecular & Cellular Proteomics, is part of a larger effort by OHSU researcher Gordon Mills to develop a cancer proteomics workflow suitable for clinical implementation.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
